Journal article
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Nature nanotechnology, Vol.12(9), pp.877-882
09/2017
DOI: 10.1038/nnano.2017.113
PMCID: PMC5587366
PMID: 28650437
Abstract
Immunotherapy holds tremendous promise for improving cancer treatment. To administer radiotherapy with immunotherapy has been shown to improve immune responses and can elicit the 'abscopal effect'. Unfortunately, response rates for this strategy remain low. Herein we report an improved cancer immunotherapy approach that utilizes antigen-capturing nanoparticles (AC-NPs). We engineered several AC-NP formulations and demonstrated that the set of protein antigens captured by each AC-NP formulation is dependent on the NP surface properties. We showed that AC-NPs deliver tumour-specific proteins to antigen-presenting cells (APCs) and significantly improve the efficacy of αPD-1 (anti-programmed cell death 1) treatment using the B16F10 melanoma model, generating up to a 20% cure rate compared with 0% without AC-NPs. Mechanistic studies revealed that AC-NPs induced an expansion of CD8
cytotoxic T cells and increased both CD4
T/T
and CD8
T/T
ratios (T
, regulatory T cells). Our work presents a novel strategy to improve cancer immunotherapy with nanotechnology.
Details
- Title: Subtitle
- Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
- Creators
- Yuanzeng Min - Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAKyle C Roche - Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAShaomin Tian - Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAMichael J Eblan - Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAKaren P McKinnon - Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAJoseph M Caster - Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAShengjie Chai - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USALaura E Herring - UNC Proteomics Core Facility, Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599, USALongzhen Zhang - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, ChinaTian Zhang - Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USAJoseph M DeSimone - Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USAJoel E Tepper - Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USABenjamin G Vincent - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAJonathan S Serody - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USAAndrew Z Wang - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
- Resource Type
- Journal article
- Publication Details
- Nature nanotechnology, Vol.12(9), pp.877-882
- DOI
- 10.1038/nnano.2017.113
- PMID
- 28650437
- PMCID
- PMC5587366
- NLM abbreviation
- Nat Nanotechnol
- ISSN
- 1748-3387
- eISSN
- 1748-3395
- Publisher
- England
- Grant note
- R21 CA182322 / NCI NIH HHS U54 CA198999 / NCI NIH HHS U54 CA151652 / NCI NIH HHS P30 CA016086 / NCI NIH HHS R01 CA178748 / NCI NIH HHS
- Language
- English
- Date published
- 09/2017
- Academic Unit
- Radiation Oncology
- Record Identifier
- 9984047657602771
Metrics
37 Record Views